Advertisement
Advertisement
U.S. Markets open in 51 mins
Advertisement
Advertisement
Advertisement
Advertisement

3SBio Inc. (1530.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
6.890-0.230 (-3.23%)
At close: 4:09PM HKT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.120
Open7.120
Bid6.880 x 0
Ask6.890 x 0
Day's Range6.830 - 7.120
52 Week Range6.160 - 12.300
Volume9,712,634
Avg. Volume8,559,349
Market Cap17.525B
Beta (5Y Monthly)0.85
PE Ratio (TTM)15.53
EPS (TTM)0.444
Earnings DateAug 16, 2021 - Aug 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 29, 2018
1y Target EstN/A
  • PR Newswire

    3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

    Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased investments in research and development, while significantly accelerating its pipeline. In the future, 3SBio will reinforce its position as an industry leader by enhancing its competitive edges with further integration of R&D, manufacturing, com

  • PR Newswire

    3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

    Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonstrated 3SBio's leading position in China's biopharmaceutical industry over the years, as well as the Company's strong growth momentum.

Advertisement
Advertisement